SmartAdjust 2.0 System With Type 1 and Type 2 Diabetes

Inclusion Criteria:

Individuals must meet all the following criteria at screening to be included in the study:

1. Age at time of consent 2-70 years (inclusive)

2. Diabetes diagnosis, based on Investigator's clinical judgement, and meets thefollowing:

• Type 1 Diabetes: 2-70 years old with A1c <11%. Diagnosed for at least 6 monthsfor participants aged 2- <7 years or at least 1 year for participants aged 7-70years. OR

• Type 2 Diabetes: 16-70 years old, diagnosed with T2D and on current insulinregimen for at least 3 months. Includes basal-bolus, pre-mix, or basal onlyusers. For basal-bolus and premix users, must have A1c < 12.0%. For basal onlyusers must have A1c > 7.0% and < 12.0%.

3. Living with a parent or guardian if < 16 years old

4. Currently using U-100 rapid-acting insulin analogs with insulin pump or basal-bolus,pre-mix, or basal only users suitable for conversion to pump therapy for at least 3months prior to study start

5. Willing to use only the following types of U-100 insulin during the study: HumalogU-100, Novorapid, or their generic equivalents

6. Deemed appropriate for pump therapy per Investigator's assessment consideringprevious history of severe hypoglycemic and hyperglycemic events, and othercomorbidities

7. Stable doses over the preceding 4 weeks of other glucose-lowering medications, asdetermined by Investigator, including within class dose equivalent medication

8. Stable doses over the preceding 4 weeks of weight loss medications that may affectglycemic control directly and/or indirectly, as determined by Investigator

9. Investigator has confidence that the participant and/or caregiver can safely operateall study devices and can adhere to the protocol

10. Willing to wear the system, including Pods, continuously throughout the study

11. If female of childbearing potential, willing and able to have pregnancy testing

Exclusion Criteria:

Individuals who meet any of the following criteria at screening will be excluded from study participation:

1. Any medical condition, which in the opinion of the Investigator, would put theparticipant at an unacceptable safety risk

2. Current or known history of coronary artery disease that is not stable with medicalmanagement, including unstable angina, or angina that prevents moderate exercisedespite medical management, or a history of myocardial infarction, percutaneouscoronary intervention, or coronary artery bypass grafting within the 12 months priorto screening

3. Any planned surgery during the study which could be considered major in the opinionof the Investigator

4. Severe retinopathy based on retinal screening performed within the last 24 months

5. History of severe hypoglycemia in the past 6 months. Severe hypoglycemia is definedas an event that requires the assistance of another person due to alteredconsciousness, and requires another person to actively administer carbohydrate,glucagon, or other resuscitative actions

6. History of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) inthe past 6 months, unrelated to an intercurrent illness or infusion failure

7. Unable to tolerate adhesive tape or has any unresolved skin condition in the area ofsensor or pump placement

8. Blood disorder or dyscrasia within 3 months prior to screening, including use ofhydroxyurea, which in the Investigator's opinion could interfere with determinationof HbA1c

9. Plans to receive blood transfusion over the course of the study

10. Pregnant or lactating, or is a woman of childbearing potential and not on acceptableform of birth control (acceptable forms of contraception include abstinence, barriermethods such as condoms, hormonal contraceptives, intrauterine device, surgicalsterilization such as tubal ligation or hysterectomy, or vasectomized partner)

11. Participation in another clinical study using an investigational drug or devicewithin 30-days or intends to participate in any other study during this study period

12. Unable to follow clinical protocol for the duration of the study or is otherwisedeemed unacceptable to participate in the study per the Investigator's clinicaljudgment

13. Participant is an employee of Insulet, an Investigator or Investigator's study team,or immediate family member of any of the aforementioned